New Study Links Fosamax to Atypical Fractures

A study published online in May 2012, by the Archives of Internal Medicine, a publication of the American Medical Association, revealed that atypical femoral fractures were associated with bisphosphonate (including Fosamax) use. Fosamax, manufactured by Merck, belongs to the class of drugs known as bisphosphonates. It was approved by the FDA in 1995 and developed to treat post-menopausal osteoporosis and Paget's disease of bone. On March 3rd, 2010, the U.S FDA issued a drug safety communication on Fosamax informing doctors and patients of a possible link between Fosamax and femur fractures. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Fosamax severe adverse events. [http://www.attorneyone.com/fosamax/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Fosamax severe adverse events threat

Fosamax severe adverse events threat

atypical femoral fractures were associated with bisphosphonate (including Fosamax) use

San Diego, CA (PRWEB) June 12, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Fosamax severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

A study published online in May 2012, by the Archives of Internal Medicine, a publication of the American Medical Association, revealed that atypical femoral fractures were associated with bisphosphonate (including Fosamax) use. Fosamax, manufactured by Merck, belongs to the class of drugs known as bisphosphonates. It was approved by the FDA in 1995 and developed to treat post-menopausal osteoporosis and Paget's disease of bone. The study conclusions mentioned that longer duration of treatment resulted in augmented risk.

According to a Wall Street Journal article published on May 21st, 2012, Merck & Co. which sells Fosamax, faces more than 3,100 product-liability lawsuits, including 1,200 alleging the drug caused jaw bones to decay in some patients, based on a recent filing it made with the Securities and Exchange Commission. On February 27th, 2012, a jury trial began in the Superior Court for Atlantic County, New Jersey in In re: Fosamax Litigation (No. 282). Plaintiffs allege that using Fosamax caused them to develop osteonecrosis of the jaw (ONJ). ONJ is a rare bone disease that can cause the patient's jaw bone to deteriorate and die.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of Fosamax severe complications, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Fosamax remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

On March 3rd, 2010, the U.S FDA issued a drug safety communication on Fosamax informing doctors and patients of a possible link between Fosamax and femur fractures.

AttorneyOne.com has further information on Fosamax lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/6/prweb9590962.htm.